- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01742195
Comparison of Patient Comfort With the Nasal and Oral Insertion of the Endobronchial Ultrasound Bronchoscope
Randomized Study Comparing the Oral and Nasal Routes for Linear Endobronchial Ultrasound
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Linear endobronchial ultrasound (EBUS) now plays a crucial role in the diagnosis, staging, and treatment planning of lung cancer. Most centers perform linear EBUS via the oral route given the larger diameter of the bronchoscope used. However, the feasibility and the diagnostic accuracy of linear EBUS performed through the nose have not been reported. Furthermore, the two routes of insertion have never been compared in terms of patient satisfaction and comfort.
In order to compare the two routes of insertion, consecutive patients referred for a linear endobronchial ultrasound will be recruited. Participants will be randomized to either oral or nasal insertion. All participants will be sedated and will receive local anesthetics in a similar manner. After the procedure, patients will fill a questionnaire regarding their comfort and satisfaction with the procedure.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Quebec
-
Québec, Quebec, Canada, G1V 4G5
- Institut universitaire de Cardiologie et de Pneumologie de Quebec
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- patients older than 18 years of age
- patients referred for a first linear endobronchial ultrasound
Exclusion Criteria:
- Patients who previously underwent an EBUS
- Patients intubated with an endotracheal tube
- Patients under the age of 18
- Patients unable to provide informed consent
- Patients currently taking anticoagulants (therapeutic doses of intravenous or subcutaneous heparin, low-molecular weight heparins, direct thrombin inhibitors or other agents)
- Patients taking anti-platelet therapy other than aspirin (clopidogrel, ticagrelor, prasugrel). A period of 7 days off medication is required before participation.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Diagnostisk
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: Nasal EBUS insertion
Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
|
|
Annen: Oral EBUS insertion
Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Patient comfort and satisfaction
Tidsramme: Two hours after endobronchial ultrasound
|
Measured by a questionnaire using a 10-point Likert scale for both comfort and satisfaction.
|
Two hours after endobronchial ultrasound
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Physician's assessment of patient comfort
Tidsramme: Immediately after the procedure (within 10 minutes)
|
Measured by a questionnaire using a 10-point Likert scale regarding patient comfort and procedural difficulties.
|
Immediately after the procedure (within 10 minutes)
|
Duration of endobronchial ultrasound procedure
Tidsramme: During the procedure
|
Measured in minutes.
|
During the procedure
|
Total doses of sedation
Tidsramme: Immediately after the procedure (within 10 minutes)
|
Total doses of each sedative used will be recorded.
|
Immediately after the procedure (within 10 minutes)
|
Occurence of pneumothorax, bleeding more than 50ml, oxygen desaturation to less than 90%, epistaxis, cardiac arrhythmia
Tidsramme: During the procedure and up to two hours after
|
During the procedure and up to two hours after
|
|
Proportion of adequate cytology specimens in each group
Tidsramme: Days after the procedure (results usually available within 10 days)
|
Days after the procedure (results usually available within 10 days)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Stéphane Beaudoin, MD, Laval University
- Hovedetterforsker: Simon Martel, MD, Laval University
- Hovedetterforsker: Antoine Delage, MD, Laval University
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- IUCPQ-20871
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Tilfredshet
-
Universiti Putra MalaysiaRekrutteringHospital Foodservice Tilfredshet; Sykehus Måltider Satisfaction; Eldre, ernæring, underernæring hos eldre, underernæringMalaysia
Kliniske studier på Nasal EBUS insertion
-
China-Japan Friendship HospitalRekrutteringMediastinal lymfadenopatiKina
-
University College London HospitalsUkjentLymfom | Lungekreft | Tuberkulose | Sarcoidose | Isolert mediastinal lymfadenopatiStorbritannia
-
University of CalgaryFullførtEBUS-TBNA opplæringsmetoderCanada
-
China-Japan Friendship HospitalHar ikke rekruttert ennåLymfadenopati Hilar | Lymfadenopati Mediastinal
-
Sanjay Gandhi Postgraduate Institute of Medical...FullførtMediastinal lymfadenopati | Hilar lymfadenopatiIndia
-
University Hospital, EssenUniversity Hospital, ZürichFullført
-
Heidelberg UniversityOlympus CorporationUkjent
-
Shanghai Chest HospitalUkjentEndobronkial ultralyd
-
Centre Hospitalier Universitaire Saint PierreSuspendert
-
University Hospital, RouenFullførtIkke småcellet lungekreftFrankrike